Form 8-K - Current report:
SEC Accession No. 0001437749-25-021062
Filing Date
2025-06-23
Accepted
2025-06-23 17:00:37
Documents
18
Period of Report
2025-06-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20250621_8k.htm   iXBRL 8-K 42074
2 EXHIBIT 1.1 ex_833149.htm EX-1.1 107069
3 EXHIBIT 4.1 ex_833150.htm EX-4.1 140209
4 EXHIBIT 10.1 ex_833252.htm EX-10.1 235940
5 EXHIBIT 99.1 ex_833151.htm EX-99.1 10687
10 a01.jpg GRAPHIC 10221
  Complete submission text file 0001437749-25-021062.txt   818469

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20250620.xsd EX-101.SCH 3579
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20250620_def.xml EX-101.DEF 11807
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20250620_lab.xml EX-101.LAB 15858
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20250620_pre.xml EX-101.PRE 12022
20 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20250621_8k_htm.xml XML 2946
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 251065622
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)